The primary objective of this project is to determine the mechanisms whereby activated leukocytes induce injury to vascular endothelial cells (EC). The proposal will test the hypothesis that ICAM-1 and VCAM mediated adhesive interactions of leukocytes with endothelial cells and concomitant leukocyte production of H2O2 upregulate the activities of endothelial cell xanthine oxidase (XO) and nitric oxide synthase (NOS), with the attendant enhanced rates of endothelial cell production of - 02-,-NO, and ONOO- mediating cell injury. In vitro models of endothelial cell interactions with ethanol fixed leukocytes and antibodies to adhesion molecules will be used to determine whether ICAM- 1 mediated adhesion of neutrophils and monocytes or VCAM mediated adhesion of mononuclear leukocytes triggers upregulation of XO or NOS activity in aortic, arterial, and venular endothelial cells. Exogenous H2O2 or HOC1 or oxidant scavengers with intact leukocytes will be added to cultured endothelial cells to determine whether generation of reactive oxygen species by adherent leukocytes is required for upregulation of XO or NOS activity. Endothelial cells pre-loaded with calcium sensitive fluorescent dyes or intracellular calcium chelator will be used to determine whether upregulation of XO or NOS activity occurring in response to adhesion of activated leukocytes on the endothelial surface is mediated by increases in cytoplasmic Ca++. Generation of ONOO- within endothelial cells will be confirmed by HPLC analysis of nitrated tyrosine residues on cellular proteins or nitration of exogenous p-hydroxyphenyl acetate added to the endothelial cells prior to incubation with activated leukocytes. The role of 'NO, ONOO-, and -ON in mediating EC cytotoxicity will be determined by measuring release of 14C-adenine from EC incubated with leukocytes in the presence of NOS inhibitor, XO inhibitor, or iron chelator. These studies will elucidate how leukocytes cause injury to vascular endothelium during acute stroke, myocardial infarction, or vasculitis.

Project Start
1999-01-01
Project End
1999-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68
Rayburn, Elizabeth R; Wang, Wei; Zhang, Zhuo et al. (2006) Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 66:1653-63

Showing the most recent 10 out of 145 publications